NGLFINENGL Fine-Chem Ltd.

₹1550+0.64%

Market Cap

₹952.19 Cr

Stock P/E

45.61

ROCE

9.44%

ROE

7.75%

Book Value

₹472.12

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Public

Others

From Last Concall

POSITIVES

•
Q4 revenue shows sequential improvement despite cyclic weakness.
•
Near-term earnings resilience evidenced by EBITDA improvement QoQ.

NEGATIVES

•
Demand and realizations under pressure due to industry overcapacity and competition.
•
Regulatory-capex ramp-up provides delayed revenue visibility (2+ years).

Peers Summary

Sector Leader

NGL Fine-Chem Ltd. exhibits solid revenue growth and reasonable profitability margins compared to its peers in the pharmaceutical industry. However, it has a high PE ratio, indicating potential overvaluation. Companies like Cipla and Dr. Reddy's Laboratories stand out as strong performers due to their high profitability and lower valuation metrics, making them attractive picks in the sector.

Key Points

• NGL Fine-Chem Ltd. shows good growth but high PE ratio (49.44) suggests overvaluation.
• Cipla and Dr. Reddy's are strong performers with robust returns and lower valuations.
• Divi's Laboratories shows weak revenue growth over three years, indicating potential concerns.

Top Performers

Cipla Ltd.

Strong profitability metrics with a low PE ratio (23.73) and solid revenue growth.

Dr. Reddy's Laboratories Ltd.

High ROE and ROA with an attractive PE ratio (15.50), indicating strong performance and value.

Explore

Watchlists

Command Palette